PMID- 29043074
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201214
IS  - 2046-1402 (Print)
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 6
DP  - 2017
TI  - Recent advances in eosinophilic esophagitis.
PG  - 1775
LID - 10.12688/f1000research.11798.1 [doi]
LID - 1775
AB  - Eosinophilic esophagitis is a chronic, antigen-driven, eosinophil-predominant 
      inflammatory disease of the esophagus and affects both children and adults. 
      Cutting-edge technologies, such as genome-wide association studies, have advanced 
      our understanding of the disease pathogenesis at a remarkable rate. Recent 
      insights from genetic and mechanistic studies have concluded that a complex 
      interplay between genetic and environmental risk factors, allergic sensitization, 
      and esophageal-specific pathways leads to disease pathogenesis. Importantly, 
      recent epidemiologic studies have found that the incidence and prevalence of 
      eosinophilic esophagitis continue to rise. New guidelines have advocated the 
      elimination of the term proton pump inhibitor (PPI)-responsive esophageal 
      eosinophilia and have recommended using PPIs as a first-line treatment modality. 
      Systemic reviews and meta-analyses confirm the efficacy of PPIs, topical 
      corticosteroids, and empiric food elimination diets. Unmet needs include the 
      development of birth cohort studies, validated diagnostic scoring systems, 
      minimally invasive disease-monitoring methods, and the development of new 
      therapies.
FAU - Durrani, Sandy
AU  - Durrani S
AUID- ORCID: 0000-0001-8311-596X
AD  - Division of Allergy and Immunology, Department of Pediatrics, Cincinnati 
      Children's Hospital Medical Center, University of Cincinnati, Cincinnati OH, 
      45529, USA.
FAU - Rothenberg, Marc
AU  - Rothenberg M
AD  - Division of Allergy and Immunology, Department of Pediatrics, Cincinnati 
      Children's Hospital Medical Center, University of Cincinnati, Cincinnati OH, 
      45529, USA.
LA  - eng
GR  - R01 AI124355/AI/NIAID NIH HHS/United States
GR  - U19 AI070235/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170928
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
PMC - PMC5621107
OTO - NOTNLM
OT  - Eosinophilic esophagitis
OT  - Proton-Pump inhibitor
OT  - Topical Croticosteroid
COIS- Competing interests: MER is a consultant for NKT Therapeutics, Pulm One, Spoon 
      Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, and Novartis and has an 
      equity interest in the first three listed and Immune Pharmaceuticals and 
      royalties from reslizumab (Teva Pharmaceuticals). He is an inventor of patents, 
      owned by Cincinnati Children's Hospital Medical Center. SRD declares that he has 
      no competing interests.No competing interests were disclosed.No competing 
      interests were disclosed.No competing interests were disclosed.No competing 
      interests were disclosed.
EDAT- 2017/10/19 06:00
MHDA- 2017/10/19 06:01
PMCR- 2017/09/28
CRDT- 2017/10/19 06:00
PHST- 2017/09/29 00:00 [accepted]
PHST- 2017/10/19 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2017/10/19 06:01 [medline]
PHST- 2017/09/28 00:00 [pmc-release]
AID - 10.12688/f1000research.11798.1 [doi]
PST - epublish
SO  - F1000Res. 2017 Sep 28;6:1775. doi: 10.12688/f1000research.11798.1. eCollection 
      2017.